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Synopsis  27 
Cutaneous leishmaniasis (CL) is one of the most disregarded tropical neglected 28 
disease with the occurrence of self-limiting ulcers and triggering mucosal damage and 29 
stigmatizing scars, leading to huge public health problems and social negative 30 
impacts. Pentavalent antimonials are the first-line drug for CL treatment for over 70 31 
years and present several drawbacks in terms of safety and efficacy. Thus, there is an 32 
urgent need to search for non-invasive, non-toxic, and potent drug candidates for CL. 33 
In this sense, we have implemented a shape-based virtual screening approach and 34 
identified a set of 32 hit compounds. In vitro phenotypic screenings were conducted 35 
using these hit compounds to check their potential leishmanicidal effect towards 36 
Leishmania amazonensis. The findings showed that two (Cp1 and Cp2) out of the 32 37 
compounds revealed promising antiparasitic activities, exhibiting considerable 38 
potency against intracellular amastigotes present in peritoneal macrophages (IC50 39 
values of 9.35 and 7.25 µM, respectively). Also, a sterile cidality profile was reached 40 
at 20 µM after 48 hours of incubation, besides a reasonable selectivity (≈8), quite 41 
similarly to pentamidine, an aromatic diamidine still in use clinically for 42 
leishmaniasis. Cp1 with an Oxazolo[4,5-b]pyridine scaffold and Cp2 with a 43 
benzimidazole scaffold could be developed further by lead optimization studies to 44 
enhance their leishmanicidal potency. 45 
 46 
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Introduction  51 
 
Cutaneous leishmaniasis (CL) is a vector-borne tropical neglected disease caused by 52 
over 20 different species of kinetoplastid parasites of the genus Leishmania. This 53 
disfiguring and stigmatizing disease occurs through the injection of promastigote 54 
forms into the mammalians by infected female sandflies, triggering ulcers and 55 
permanent scars at skin and/or oral and nasal mucosa injuries, thus contributing to 56 
high social stigmatization and public health issue (WHO, 2020). Although about 57 
1,2 million of new cases occur annually, CL does not have adequate treatment that 58 
are mostly based on old and highly toxic drugs besides the occurrence of high number 59 
of parasite species with drug resistance profile (Bailey et al., 2019, Alvar et al., 2012, 60 
de Vries et al., 2015, Van Bocxlaer et al., 2019).  61 
First line treatments include the clinical use of pentavalent antimonials drugs 62 
developed 70 years ago that present several drawbacks in terms of efficacy, safety and 63 
require long painful periods of administration (Eiras et al., 2015, DNDi 2018). In the 64 
case of antimonial resistance, the second-choice therapy includes pentamidine and 65 
amphotericin B (deoxycholate), which also share the previous reported concerns and 66 
limitations (Croft 2006, de Vries et al., 2015). Up to now, the only oral and less toxic 67 
alternative drug – Milteforan – is unavailable in many developing poorest countries 68 
(Bilgic Temel 2019). Besides, the safer liposomal formulation of amphotericin B is 69 
highly costly and still under evaluation for effectiveness against CL (Shirzadi 2019). 70 
Last clinical trials for CL were mostly based on drug repurposing and/or combination 71 
but unfortunately the overall findings were not very successful to demonstrate an 72 
improvement of therapeutic efficacy, such as the combination of Pentavalent 73 
antimonial with imiquimoid (Miranda-Verastequi et al., 2009) and the topical use of 74 
3% amphotericin B (Lopez et al., 2018). A phase II clinical trial regarding a shorter 75 
course of oral miltefosine administrated in combination with thermotherapy, 76 
 
conducted in Peru and Colombia, ended in 2019 but the outcomes were not published 77 
yet (Valencia et al., 2013, https://www.dndi.org/diseases-projects/portfolio/new-cl-78 
combos). 79 
Computer aided drug design is an efficient strategy to identity active compounds. 80 
Shape-based screening has been successfully employed for the development of anti-81 
fungal and anti-bacterial agents (Swinney & Anthony, 2011). To employ this 82 
approach, 3D structure of the target protein/receptor is not required. However, an 83 
established active compound (defined as a query compound) against a target is a 84 
starting point for this approach. The purpose of the shape-based screening is to 85 
identify chemically diverse compounds that show similar biological activity as the 86 
query compound. This is based on the principle that diverse structures that share 87 
similar shape and electrostatic potential surface, or topology will have highest 88 
probability to bind to the same pocket and consequently share the similar activity 89 
(Kumar & Zhang, 2018). Due to the limited information on target proteins of 90 
Leishmania amazonensis and the non-availability of quality 3D structures of target 91 
proteins, we have carried out ligand-based shape screening approach using an 92 
established active compound GNF5343 that is reported to display broad spectral anti-93 
parasitic activity (Khare et al., 2016). We have identified a set of 32 hit compounds 94 
from this study. Thus, the urgent need for safer and selective potent drugs associated 95 
with promising aspects of identified diverse hit compounds encouraged us to perform 96 
in vitro phenotypic screening of these compounds upon amastigotes of  Leishmania 97 
amazonensis, which is one of the main agents of CL in the Americas (Martins 2014, 98 





Compounds: All 32 identified hit compounds (Chart 1 and Figure 1) that were 103 
purchased from Asinex commercial vendor and the reference drug, Pentamidine (Pt), 104 
were dissolved in DMSO (stock solutions at 20 mM) and fresh dilutions prepared 105 
extemporaneously, with the final concentration never exceeding 0.6% for in vitro 106 
experiments, which does not induce host cell toxicity (Santos et al., 2019).  107 
Parasite strain and mammalian host cell cultures: Leishmania amazonensis (strain 108 
LTB0016) was used throughout the study. Male BALB/c mice were infected (106 109 
amastigotes/20 µL culture medium, via subcutaneous) at their foot paws, using a BD 110 
ultrafineTM 6 mm syringe (15/64”) x 31 G, following previous reported protocol, with 111 
minor modifications (Van Bocklaer et al., 2019). After 30 days post infection, the 112 
animal skin lesions were aseptically removed, and the parasites obtained by mechanic 113 
dissociation (pipetting). The purified amastigotes were then assayed directly with the 114 
studied compounds to check the activity upon free amastigote forms (FA), or used to 115 
infect primary cultures of peritoneal macrophages (PMM) to investigate their potency 116 
against intracellular forms (IA) (Feitosa LM et al., 2019). Swiss male mice (18-20 g) 117 
were inoculated with 3% thioglycolate, and after 4 days, PMM collected by rinsing 118 
the animals’ peritoneum with RPMI 1640. Mammalian cells were seeded at 24 (3x105 119 
cells/well) and 96-wells (5x104 cells/well) plates and used for in vitro infection and 120 
host cell cytotoxicity analysis, respectively. The cultures were sustained at 37°C with 121 
5% C02 atmosphere in RPMI 1-640 medium (pH 7.2 to 7.4) without phenol red (Gibco 122 
BRL) but supplemented with 1% L-glutamine, 1% PEN-STR, 10% fetal bovine serum 123 
(FBS). Assays using FA were also maintained at 32ºC using the same RPMI culture 124 
medium but adding 5% FBS instead of 10%.  125 
 
Cytotoxicity upon mammalian host cells and leishmanicidal analysis: For cytotoxicity 126 
analysis, PMM were incubated for 48h with increasing concentrations of the tested 127 
compounds (up to 500 µM). Cellular viability was evaluated by AlamarBlue tests 128 
(Invitrogen) following the manufacturer’s instructions (Da Silva et al., 2007, 129 
Romanha et al., 2010). The leishmanicidal activity was explored in two steps: in the 130 
first set of assays, amastigotes (106 parasites per well in 0.2mL) purified from animal 131 
lesions (free amastigotes  -FA) were exposed for 48 h using a fixed concentration (10 132 
µM), and then, drug activity assessed by AlamarBlue tests (Mikus J & Sterverding D, 133 
2000). Then, in a second set of phenotypic screenings, the activity of the compounds 134 
was further validated upon intracellular amastigotes (IA). In these assays, PMM 135 
(3x105) were infected with amastigotes (9x105 amastigotes) using MOI 3:1 (Van 136 
Bocxlaer et al., 2019). After 48 h of compound incubation (0-20 µM), infected PMM 137 
were rinsed with saline buffered with phosphate (PBS), fixed with Bouin and stained 138 
with Giemsa solution for light microscopy analysis (Santos et al., 2019). Then, the 139 
percentage of infected host cells and the number of parasites per infected cells were 140 
scored for determination of the corresponding infection index (II) that represents the 141 
multiplication factor of both parameters. Only characteristic parasite nuclei and 142 
kinetoplasts were counted as surviving parasites since irregular structures could mean 143 
parasites undergoing death. The results were expressed as % of reduction of the 144 
parasite burden and the IC50 and IC90 calculated (Santos et al., 2019). All assays were 145 
run in at least twice in three independent repeats. 146 
Compound database preparation: Using the LigPrep module of the Schrödinger drug 147 
design software, a database (Asinex gold) of commercially available compounds was 148 
prepared by performing 2D to 3D conversion, addition of hydrogens, generation of 149 
ionization states, tautomeric states, stereoisomers and ring conformations at the 150 
 
physiological pH 7.0 ± 2.0. Further, energy minimization of all the compounds was 151 
carried out using the molecular mechanics OPLS3 force field. 152 
Results 153 
Shape-based virtual screening: Compound GNF5343, an Oxazolo[4,5-b]pyridine 154 
derivative (Figure 1) was reported to display activity against Leishmania donovani, 155 
Trypanosoma cruzi and Trypanosoma brucei (Khare et al., 2016). This compound 156 
was used as a query compound to perform the virtual screening of a set of 60,000 157 
chemically diverse compounds from the Asinex database. These compounds were 158 
selected by applying the Lipinski filter (Mol.Wt ≤ 500; cLogP ≤ 5; HBA ≤ 10; HBD 159 
≤ 5), removing the compounds with nitro groups and reactive functional groups 160 
(QikProp, Schrödinger release 2017-2). Using the shape-based virtual screening 161 
approach, each conformer of the molecule from the database was aligned to the query 162 
compound and phase sim score was computed based on the maximum overlapping 163 
characteristics. Compounds with shape sim score between 0.85 to 0.6 were visually 164 
inspected to assess the structural diversity and synthetic accessibility. Based on these 165 
criteria, a subset of 31 compounds (Chart 1) was selected and Hierarchical clustering 166 
was performed, in which 2D fingerprints and atom pairs were used as metrics to 167 
quantify the chemical diversity (Canvas, Schrödinger release 2017-2). A total of 11 168 
clusters were identified, of which five were singletons with diverse chemical 169 
structures such as Quinoxaline derivative (cluster 4), Imidazo[2,1-b]thiazole 170 
derivative (cluster 6), benzoxazole derivative (cluster 9), 2-oxo-2H-chromene 171 
derivative (cluster 10) and 3-imidazo[1,2-a] pyridine derivative (cluster 11). As the 172 
query compound GNF5343 was not available for purchase, we have selected one of 173 
its close analogue Cp1 (Figure 1) for the comparative studies along with the selected 174 
set of 31 hit compounds. Cp1 differs from GNF5343 in having a thiophenyl ring 175 
 
substitution instead of furyl ring. All 32 compounds were purchased from Asinex and 176 
assayed using different protocols in vitro. A fixed concentration (10 µM) was first 177 
assessed on free amastigotes (FA) and findings demonstrated that two (Cp1 and Cp2) 178 
out of the 32 compounds reduced (≥ 50 %) the number of live parasites. Analogues 179 
of Cp2 from cluster 1 (Chart 1: 2a and 2b) displayed weak inhibition. Compounds 180 
from other clusters did not show any activity. While Cp1 is a close analogue of query 181 
compound, Cp2 is structurally diverse from GNF5343 in having benzimidazole 182 
scaffold. Both GNF5343 and Cp2 displayed good alignment and maximum volume 183 
overlap (Figure 1) indicating that these two compounds are having similar topology 184 
to form similar van der Waals surface interactions at the same region. It is interesting 185 
to notice the varied distribution of hydrogen bond donors (HBD), hydrogen bond 186 
acceptors (HBA) and hydrophobicity between the basic scaffolds (Oxazolo[4,5-187 
b]pyridine Vs benzimidazole) of GNF5343 and Cp2. These active compounds (Cp1 188 
and Cp2) and the reference drug Pentamidine (Pt) were further analyzed against FA 189 
using increasing concentrations of the tested compounds and Pt. The findings showed 190 
moderate leishmanicidal effect, with IC50 values of 14.93 and 15.86 µM for Cp1 and 191 
Cp2 respectively, being less potent than Pt (0.71 µM) (Table 1). In the second round 192 
of assays, the compounds were further evaluated against intracellular amastigotes 193 
present in the cytoplasm of PPM, which represent the gold models for in vitro 194 
screening of leishmanicidal agents (DNDi, 2018). Our data showed that both 195 
compounds were active upon IA, exhibiting IC50 values of 7 and 8.50 µM, 196 
respectively, while Pt gave 1.94 µM (Table 1). Against the IA, Cp1 and Cp2 reached 197 
low IC90 values (17.25 ± 0.21 µM and 18.54±0.96 µM), exhibiting a leishmanicidal 198 
profile since both drastically dropped the number of parasites per cells as well as the 199 
percentage of infected PMM (Figure 2). Regarding the mammalian host cell toxicity, 200 
 
we found that after 48 h of exposure, Cp1 and Cp2 were about 3-fold less toxic as 201 
compared to Pt, giving IC50 of 62.75±0.27 and 65.39±0.61, with selectivity indexes 202 
of 6 and 9, respectively,  in similar range than the reference drug (SI = 8,  Table 1).  203 
In silico assessment of drug likeness and DMPK properties is most effective way in 204 
reducing time, expenses and maximize the success in drug discovery process 205 
(Lombardo et al., 2017). Therefore, drug likeness and DMPK properties were 206 
predicted for both Cp1 and Cp2 using the QikProp module (QikProp, Schrödinger 207 
release 2017-2). Recommended compliance scores are given in Table 2. The predicted 208 
properties of Cp1 and Cp2 showed compliance with “Lipinski rule of five”. According 209 
to “Jorgensen rule of three” any compound that meet the recommended criteria (Table 210 
2) are more likely to be orally available. The predicted properties of both Cp1 and 211 
Cp2 displayed compliance with “Jorgensen rule of three”. Hence these compounds 212 
could show good permeability and solubility properties. Both these properties are 213 
crucial for good oral bioavailability. QPPMDCK values are the prediction of MDCK 214 
cell permeability (nm/s) which is a good mimic for blood brain permeation. According 215 
to this, both compounds displayed good blood brain permeation. The efficiency of a 216 
drug may be affected by the extent at which it binds to human plasma protein. If 217 
compounds show high binding affinity to serum albumin this could lead to poor 218 
efficacy. Hence it is very crucial to understand the binding characteristics of Cp1 and 219 
Cp2. The predicted human serum albumin binding values (Table 2) for both Cp1 and 220 
Cp2 are within the permissible range indicating a lower binding affinity to the serum 221 






The entire process of drug discovery is extremely costly and takes at least one decade 227 
of pre-clinical and clinical studies: 1 out of 10,000 drug candidates succeeds in this 228 
long flowchart, and finally reaches successfully into the market (Van Norman 2016). 229 
In this context, more reliable and reproductible experimental models (in vitro and in 230 
vivo) are needed to find better translation among pre-clinical and clinical outcomes of 231 
novel antiparasitic drugs (Chatelain & Konar 2015, Katsuno 2015). Presently, our 232 
analysis was performed using primary cultures of peritoneal macrophages infected 233 
with L. amazonensis since professional phagocytes are the main source of host cells 234 
for those obligate intracellular parasites (Walker et al., 2015). This in vitro 235 
standardized experimental model for CL is claimed to closely reproduce in vivo 236 
conditions (Stacey 2006), therefore contributing to novel drug candidate screenings 237 
for this neglected illness (Chatelain & Ioset 2011, Caridha et al., 2019). Also, 238 
although in Asia and Africa continents CL is mainly caused by L. major and L. tropica; 239 
in the Americas, the disease is trigged by a higher number of species including L. 240 
amazonensis, justifying the present use of this parasite species (Martins 2014, de 241 
Vries et al., 2015).  L. amazonensis is a relevant species in Brazil closely related to a 242 
wide spectrum of CL pathologies, including highly severe diffuse cutaneous 243 
leishmaniasis (Lainson, 1994). These data corroborate the choice of our in vitro model 244 
to explore the potential effect of novel anti-CL compounds. Another interesting point 245 
to be addressed is the use of protocols that enable the identification of antiparasitic 246 
drugs that induces rapid parasite lysis (Da Silva et al., 2011).This is especial 247 
characteristic as most of the CL patients live in very poor areas with difficult access 248 
to public health assistance and then, frequently display advanced pathologies, 249 
demanding a fast killer drug (Ruoti et al., 2013, Okwor & Uzonna 2016). Aiming to 250 
 
fulfill this demand, we established a period of 48 h of drug exposure while testing the 251 
parasites and host mammalian cells, a shorter period of incubation as compared others 252 
reported in the current literature for CL in vitro models (Van Bocklaer, 2019). 253 
Our present study explored the leishmanicidal effect of Cp1 (an analogue of 254 
GNF5343) and Cp2 (a benzimidazole analogue) identified using shape-based virtual 255 
screening approach. Both Cp1 and Cp2 achieved quite relevant potency against 256 
amastigotes, especially those lodge inside macrophages, reaching IC50 values below 257 
10 µM, a considerable characteristic preconized for a hit compound with anti-258 
leishmania effect (Katsuno, 2015). Remarkably, clearance on L. amazonensis 259 
infection was found at 20 µM in the infected PMM, a relevant feature to mitigate the 260 
possible occurrence of parasite drug resistance and relapses after ceasing the drug 261 
administration (Cal et al., 2016). The Cp1 and Cp2 were less toxic than the reference 262 
drug (pentamidine) still in use for Leishmaniasis but their selectivity indexes (>10) 263 
discouraged to move them for in vivo proof of concept. However, their chemical 264 
optimization for a wider therapeutic window and promotion of potency is largely 265 
desirable to continue further studies using these compounds. It is also important to 266 
state that the first-line drug pentamidine – used to treat the first stage of Sleeping 267 
Sickness and CL-caused by L. guyanensis by over seven decades – also doesn’t have 268 
a desirable selectiveness in vitro due to high toxic profile, although display an 269 
outstanding potency against these parasites. Currently, we are performing structural 270 
modifications of Cp2 aiming to improve its potency, selectivity and satisfactory 271 
pharmacological profile, favoring future phenotypic studies in order to move its 272 
derivatives forward to new in vitro screening and in vivo evaluation, aiming to 273 
contribute for drug discovery process of new therapeutic approaches for cutaneous 274 
 
leishmaniasis. These analogues will also be tested against other parasites to assess 275 
their broad-spectrum antiparasitic activity. 276 
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Figure 1.  Shape-based virtual screening results. a) Illustrating the good alignment of 449 
query compound GNF5343 (orange sticks) with compound 2 (atom type coloured sticks). 450 
b) Displaying maximum volume overlap that indicates good shape complementarity 451 
between the query compound (represented with mesh with an area of 300 Å²) and the 452 
compound 2 (represented with van der Waals molecular surface area of 326.5 Å²).               453 
c) Molecular structures and their associated activity data. 1a & 1b Images are generated 454 
































Cluster 1: Benzimidazole derivatives

































































































































































































































Figure 2. Light microscopy images of Giemsa-stained uninfected and infected PMM 472 
submitted or not (untreated) to 10 and 20 µM of Cp1 and Cp2, demonstrating parasite 473 











Table 1. The leishmanicidal activity and cytotoxicity effect (IC50 - mean and SD) on 484 
peritoneal macrophage (PMM) of Cp1 and Cp2. The compounds were tested (48 hours 485 
of incubation) upon amastigote forms purified from mice lesions (FA) and on 486 
intracellular amastigote forms (IA) hosted in PMM. SI: selective indexes.  487 
 488 
Compound IC50 (µM) PMM IC50 (µM) FA IC50 (µM) IA SI FA SI IA 
Cp 1 62.75±0.27 13.03±2.69 9.35±1.87 4.82 6.71 
Cp 2 65.39±0.61 14.09±2.24 7.25±1.46 4.64 9.02 


















Mol.Wt ≤ 500 355.80 365.794 
HBD ≤ 5 1 2 
HBA ≤ 10 4 2 
cLogP ≤5 3.36 4.59 
 
Jorgensen 
Rule of three 







<7 3 0 
% Human oral 
absorption 
- 
>80% is high, 
<25% is low 
100 100 
QPPMDCK - 
>500 great, <25 
poor 
2650 3285 
QPlogKhsa - –1.5 to 1.5 0.243 0.616 
Mol.Wt: Molecular Weight; HBD: hydrogen bond donor; HBA: hydrogen bond acceptor; cLogP: 494 
calculated logarithm of partition coefficient; QPlogS: the logarithm of aqueous solubility; 495 
QPCaco: Caco-2 cell permeability in nm/sec, model for the gut-blood barrier; QPPMDCK: 496 
Madin-Darby canine kidney (MDCK) cell permeability in nm/sec, model for the blood-brain 497 
barrier; QPlogKhsa: the logarithm of predicted binding constant to human serum albumin. 498 
 499 
 500 
